Clinquest Group of Amsterdam, The Netherlands and TNO of Delft, The Netherlands, have signed a license and collaboration agreement that provides Clinquest with the exclusive rights to worldwide clinical development and commercialization of CQ-07001, a highly promising candidate for anti-inflammatory and tissue regeneration applications. Under the terms of the agreement, TNO will receive milestone fees and royalty payments, but financial details were not disclosed.
